Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CISS: Allogeneic MSCs for Septic Shock
NCT02421484Phase 1Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- May 2015
- Primary completion
- Jun 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL) in septic shock, sponsored by Ottawa Hospital Research Institute. Primary endpoint: Number of adverse events as a measure of safety and tolerability at 12 months. Started May 2015; status: completed.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL)
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT02421484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02421484.